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Recent in vitro functional data (Storey et al, 1998) suggests that
the arginine variant at codon 72 of the p53 tumour suppressor
gene is more susceptible to degradation by oncogenic human
papillomavirus (HPV) E6 protein than the proline variant.
Preliminary epidemiological data (Storey et al, 1998) found that
women with cervical cancer were more likely to be homozygous
for arginine than healthy controls. However, several larger studies
from Europe (Hayes et al, 1998; Helland et al, 1998; Joseffson et
al, 1998; Lanham et al, 1998; Rosenthal et al, 1998), the USA
(Hildesheim et al, 1998; Sonada et al, 1999), Japan (Wang et al,
1999) and China (Minaguchi et al, 1998; Ngan et al, 1999a) have
failed to reproduce this finding. Nevertheless, one large European
study (Zehbe et al, 1999) has found an excess of arginine homozy-
gotes in cervical cancer patients from both Italy and Sweden
compared with healthy controls. A weaker association was found
with pre-invasive disease.
Studies of this polymorphism in the context of HPV infection
have to date been limited to cervical cancer. Recent studies in head
and neck cancer (Hamel et al, 2000) and skin cancer (Marshall et
al, 2000) found no association between the polymorphism and
malignancy, however neither study tested for HPV status, even
though HPV is implicated in only a proportion of these cancers. As
vulval cancer and intraepithelial neoplasia are often associated
with HPV infection, we decided to investigate this polymorphism
in UK women with vulval intraepithelial neoplasia (VIN) and
invasive vulval squamous cell carcinoma (VSCC). While the
vast majority of VIN is associated with oncogenic HPV types
(Kohlberger et al, 1998), this is not the case with VSCC, in which
only 15–57% of samples may contain HPV DNA (Lee et al, 1994;
Kagie et al, 1997). We therefore initially tested our formalin-fixed
tissue samples for the presence of genital HPV types.
MATERIALS AND METHODS
Populations studied and extraction of DNA
Samples containing both normal and neoplastic tissue (either VIN,
VSCC or both) from UK caucasian women were retrieved from the
pathology archives of St. Bartholomew’s and the Royal London
hospitals. The relevant paraffin-embedded tissue samples were seri-
ally sectioned as follows: one 4-micron section was mounted,
stained with haematoxylin and eosin (H+E), covered and used as a
reference slide. One 10-micron section was also stained with H+E,
but left uncovered. The uncovered 10-micron section was mounted
on a dissecting microscope and compared with the reference slide.
Areas of tissue containing > 70% VSCC, VIN or normal tissue were
identified by a histopathologist and microdissected. DNA extraction
was performed in 100 ml of 10% Chelex chelating resin (Sigma,
Saint Louis, MS, USA) and 200 mg ml–1 proteinase K (Boehringer
Mannheim, Lewes, UK), vortexed, placed in a shaking water bath at
56°C for 30 min and boiled for 8 min to inactivate the enzyme. The
sample was centrifuged at 10 000 g for 10 min to pellet any
remaining debris. 1–4 ml of supernatant was used directly in the
polymerase chain reaction (PCR). The control population used was
that described in our previous study (Rosenthal et al, 1998). Briefly,
this comprised DNA extracted from 96 caucasian women from
different parts of the UK taking part in a randomized controlled trial
of ovarian cancer screening and 150 caucasian women attending for
routine antenatal care in the Oxford region of the UK. The p53
codon 72 genotype frequencies did not differ significantly between
these two groups and so they were combined for the purpose of
statistical comparison with the study groups, as in our original study
(Rosenthal et al, 1998).
PCR amplification of consensus genital-type HPV L1
gene
PCR in a Touchdown Thermal Cycler (Hybaid, Asford, UK) was
performed in 20 ml containing 0.2 mM deoxyribonucleotide triph-
osphates, 0.25 U of Taq supreme DNA polymerase (Hellena
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and 20 pmol each of primers GP5+ and GP6+ (Kohlberger et al,
1998). PCR was performed using a 3 min denaturation step at
94°C followed by 40 cycles of denaturation at 94°C for 1 min,
annealing at 48°C for 2 min and extension at 72°C for 1.5 min. A
final extension step at 72°C for 7 min was performed. Hela cell
DNA was used as positive control and cross-contamination was
checked for using water controls. PCR products were elec-
trophoresed on a 2% agarose gel and visualized using ethydium
bromide staining and ultraviolet illumination.
PCR amplification of p53 codon 72 polymorphic alleles
PCR in a Touchdown Thermal Cycler (Hybaid, Asford, UK) was
performed in a volume of 20 ml containing approximately 20–100
ng DNA extracted from microdissected normal tissue, 80 mM
deoxynucleotide triphosphates, 0.1 U of Red Hot DNA poly-
merase (Advanced Biotechnologies, Epsom, UK), 1 ´ buffer
(supplied with enzyme), 1.5 mM Mg2+, 1.5 pmol of forward
primer, 2 pmol of reverse primer and 0.5 pmol of 32P-labelled
forward primer. Primers for the arginine allele have been previ-
ously described (Storey et al, 1998). Primers for the proline allele
were as follows: 5¢-GCCAGAGGCTGCTCCCCC and 5¢-
GAAGGGACAGAAGATGACAGG. PCR for the arginine allele
was performed using a 5 min denaturation step at 94°C followed
by 35 cycles of denaturation at 94°C for 1 min, annealing at 54°C
for 1 min and extension at 72°C for 1 min. A final extension step
at 72°C for 5 min was performed. PCR for the proline allele was
performed using the same conditions as those for the arginine
allele, except for a different annealing temperature of 58°C.
Homozygous arginine and proline controls were used. The PCR
products were electrophoresed on a 5% denaturing polyacrylamide
gel. Autoradiography was performed. The arginine-specific PCR
results in a 141 base-pair product and the proline-specific PCR
results in a 101 base-pair product. The reliability of this assay was
confirmed by direct sequencing of products amplified from the
control samples from our original study (Rosenthal et al, 1998).
Statistical analysis
95% confidence intervals for the observed genotype frequencies
were calculated. The chi-squared test was used to establish
whether the sample and control groups were in Hardy–Weinberg
equilibrium and whether the proportions of the three p53 codon 72
genotypes differed between the sample and control groups.
RESULTS
We identified 48 cases of VIN not associated with VSCC and 52
cases of VSCC which were HPV-positive. The results of the
analysis are shown in Figure 1, along with the results of the control
populations from our previous study (Rosenthal et al, 1998). There
were significant differences in the proportions of the three p53
codon 72 genotypes (arginine homozygotes, proline homozygotes
and heterozygotes) for both vulval cancer vs controls (df = 2,
P = 0.0023, c2 = 12.11) and for VIN vs controls (df = 2, P <
0.0001,  c2 = 22.21). These differences resulted from a lower
frequency of arginine homozygotes in both the vulval cancer
group (42%) and the VIN group (29%) compared with the control
group (63%). The control population was in Hardy–Weinberg
equilibrium (df = 1, P = 0.123, c2 = 2.38), but neither the vulval
cancer nor the VIN populations were in equilibrium (vulval cancer
df = 1, P = 0.016, c2 = 5.76; VIN df = 1, P = 0.003, c2 = 8.56).
DISCUSSION
If women homozygous for the arginine variant of the p53 codon 72
polymorphism are at increased risk of cervical cancer (Storey et al,
1998), then this has important implications for targeting cervical
screening to a high-risk population. As the polymorphism was
thought to increase cervical cancer risk by rendering p53 product
more susceptible to HPV E6-mediated degradation, the arginine
variant might also be expected to increase the risk of other ano-
genital HPV-associated neoplasias. Included in this group are VIN
and some VSCC, in which the predominant HPV is the oncogenic
type 16 (Hording et al, 1993; Lee et al, 1994; Kagie et al, 1997;
Ngan et al, 1999b). We therefore tested the hypothesis that HPV-
positive VIN and VSCC were associated with being homozygous
for the arginine variant. If such an association were found, such
women might benefit from increased surveillance. This study is the
first to examine the relationship between p53 codon 72 poly-
morphism and proven HPV-associated neoplasia outside the cervix.
We demonstrated a significant association between the p53
codon 72 polymorphism genotype and the type of sample studied.
However, in contrast to the two previous positive studies in
cervical cancer (Storey et al, 1998; Zehbe et al, 1999), we
observed a lower frequency of arginine homozygotes in the HPV-
associated vulval cancer and VIN patients than in healthy controls.
This suggests that arginine homozygotes have a lower risk of
developing vulval neoplasia, compared with women who have 
one or more proline alleles. This is supported by the observation
that neither the VSCC nor the VIN population were in
Hardy–Weinberg equilibrium, indicating that the presence of a
proline allele appears to select in favour of the vulval neoplasia
phenotype. We are unaware of any biologically plausible reason as
to why the arginine variant might confer protection, but it is inter-
esting to note that studies of lung (Birgander et al, 1995) and
nasopharyngeal cancer (Birgander et al, 1996) have also demon-
strated an association between the proline allele and disease.
However, the risk of the proline allele applied mostly in combina-
tion with the presence of a 16 base-pair duplication in intron 3 of
the p53 gene. This suggests that the proline allele may be a marker
1288 AN Rosenthal et al
British Journal of Cancer (2000) 83(10), 1287–1290 © 2000 Cancer Research Campaign
Heterozygotes Proline
homozygotes
Arginine
homozygotes
VIN not associated with VSCC (n = 48)
VSCC (n = 52)
Controls (n = 246)
%
 
o
f
 
p
o
p
u
l
a
t
i
o
n
 
w
i
t
h
 
g
i
v
e
n
 
g
e
n
o
t
y
p
e
0
10
20
30
40
50
60
70
80
Figure 1 Distribution of p53 codon 72 alleles in women with VIN, women
with VSCC and healthy controls (error bars = 95% confidence intervals)for linkage disequilibrium with a functional cancer susceptibility
site elsewhere in the gene.
Eleven of 13 different populations reported in the 11 studies so
far published have failed to demonstrate an association between
p53 codon 72 polymorphism and cervical cancer, while two have
found a positive association between this disease and the arginine
variant. There are three possible explanations for the conflicting
results in these studies. First, accidental inclusion of HPV-negative
cancers in some of the studies could have diluted the true study
population. This criticism is not relevant in cervical cancer where
almost all squamous cell carcinomas (SCC) are associated with
HPV (Walboomers et al, 1999). It could be argued that of the
oncogenic HPV types, only HPV 16 and 18 E6 proteins have been
shown to degrade the arginine variant of p53 more easily than the
proline variant (Storey et al, 1998) and that other types of onco-
genic HPV may not exhibit this property. However approximately
75% of cervical SCC in Europe contain these two types of HPV
(Bosch et al, 1995), so this is an unlikely explanation. In the 
case of vulval cancer, not all cases are HPV-positive, so we used
sensitive consensus primers to detect genital HPV types and only
performed the polymorphism analysis in HPV-positive cancers.
Previous studies (Hording et al, 1993; Lee et al, 1994; Kagie et al,
1997; Ngan et al, 1999b) have demonstrated that the vast majority
of HPV-positive VSCC contains type 16.
A second possible explanation for discrepant results in polymor-
phism studies is accidental inclusion of people from different
ethnic groups. We were careful to ensure that only UK caucasian
women were included in both our previous study and this study.
The other studies of this polymorphism describe ethnic matching
of cases and controls. It is interesting to note that the UK caucasian
control population from the original pilot study (Storey et al, 1998)
had different allele frequencies to the larger UK caucasian popula-
tions in subsequent studies (Rosenthal et al, 1998; Lanham et al,
1998). While the pilot study control population allele frequencies
may not have been statistically in disequilibrium, this may reflect
the relatively small sample size.
The third possible explanation for discrepant results is the accu-
racy of the polymorphism assay used. While we cannot comment
on different methods used by other groups, our previous report
(Rosenthal et al, 1998) used the same technique as that used in the
pilot study (Storey et al, 1998). We modified this technique in the
current study because the frequency of loss of heterozygosity at
the p53 locus in VSCC or VIN has not yet been reported. It is
therefore possible that performing the polymorphism assay on
samples containing neoplastic tissue could underestimate the
proportion of true heterozygotes if some of them had lost one copy
of the p53 locus. We therefore tested microdissected normal tissue.
It was necessary to redesign one of the primers for amplification of
the proline allele in order to yield a relatively smaller product,
which could be reliably amplified from the lower concentrations of
DNA obtained from microdissected tissue. Direct sequencing of
this product confirmed that it amplified the proline variant.
In conclusion, the balance of evidence suggests that the arginine
polymorphism, while functionally different from the proline in
vitro, does not appear to be associated with an increased risk of
cervical neoplasia. Even if much larger studies were to refute this
conclusion, the high frequency of arginine homozygotes in
Northern European populations means that this polymorphism is
unlikely to be useful as a test to identify women at higher risk of
cervical cancer in such populations. In contrast to the evidence 
in cervical cancer, our data suggests that the arginine variant 
may protect against the development of HPV-associated vulval
neoplasia.
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